Fertility consolidation begins, and Celcuity lands its first approval

Onto Health absorbs Levy Health, Celcuity clears its first drug, and a national strategy puts a price on the gap. Seven minutes.

Two signals worth holding next to each other this week. Onto Health, three months off a $20M Series A, acquired Levy Health to fold fertility diagnostics into its own infrastructure — the kind of tuck-in that marks a sector moving from land-grab to consolidation. At the same time, a national strategy put a number on the problem the whole category is built around: $20 billion over ten years to close the women's health gap. One is private capital integrating vertically. The other is public capital being asked to show up at all. The distance between those two numbers — a $20M startup round and a $20B national ask — is roughly the shape of the funding gap femtech keeps trying to close from the bottom up. Below: Celcuity's first drug approval, positive Phase 2 data for a non-hormonal hair loss drug in women, and the week's remaining moves.